This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.
July 06, 2016
Targovax presents encouraging preclinical data on ONCOS-102
July 01, 2016
Targovax ASA: Applies for listing of its shares on Oslo Axess
July 01, 2016
Targovax recruits the first patient in a trial with the oncolytic virus ONCOS-102 in malignant pleural mesothelioma
June 30, 2016
Orexo signs license agreement with Mundipharma, which obtains ex-US global rights to Zubsolv®
June 30, 2016
Nexstim Plc Receives CE Mark Registration for NBT® for Treatment of Chronic Neuropathic Pain
June 28, 2016
Nexstim Plc Key Technology Patent Granted in US
June 28, 2016
Nexstim Plc submits FDA 510(k) De Novo documentation for NBT®
June 28, 2016
Nordic Nanovector and AREVA Med to investigate potential of lead-212 conjugated anti-CD37 antibody for treating leukaemias
June 22, 2016
Targovax ASA: Announcement of successful NOK 110 million private placement
June 14, 2016
Strongbridge Biopharma plc to Participate in the JMP Securities Life Sciences Conference and 3rd Annual ROTH Healthcare Day in London